Loading...
The preliminary report from the randomized RECOVERY clinical trial (NEJM JW Infect Dis Sep 2020 and N Engl J Med 2020 Jul 17; [e-pub]) demonstrated that 10 days of dexamethasone resulted in a mortality benefit in hospitalized COVID-19 patients, especially those on mechanical ventilation. Investigators at a referral center in Brazil have now performed a double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy of a 5-day course of methylprednisolone (MP) at reducing the mortality of patients hospitalized with COVID-19.
Of 416 patients randomized, 393 (mean age, 55 years) completed follow-up: 194 in the MP arm and 199 in the placebo arm. No patient received remdesivir, anti-IL-6, or anti-IL-1 agents. The most common c…